Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1642678 | 0.83 | DAO (0.39) | RAB9ATSHRL3MBTL1KMT2AMEN1 | |
| SCHEMBL5788693 | 0.78 | NOTUM (0.47) | RAB9ATSHRL3MBTL1KMT2AMEN1 | |
| SCHEMBL4919212 | 0.74 | L3MBTL1 (0.41) | TSHRL3MBTL1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL9587424 | 0.74 | BCHE (0.37) | RAB9AL3MBTL1SMN1; SMN2NPC1HPGD | |
| SCHEMBL289936 | 0.70 | NR1H2 (0.42) | L3MBTL1 | |
| SCHEMBL1643083 | 0.68 | HPGD (0.44) | RAB9ATSHRL3MBTL1KMT2AHPGD | |
| SCHEMBL31435512 | 0.67 | RAB9A (1.00) | RAB9ATSHRL3MBTL1KMT2AMEN1 | |
| SCHEMBL1413391 | 0.67 | RAB9A (1.00) | RAB9ATSHRL3MBTL1KMT2AMEN1 | |
| SCHEMBL4421581 | 0.67 | RAB9A (0.55) | RAB9ATSHRL3MBTL1KMT2AMEN1 | |
| SCHEMBL3849038 | 0.66 | CA12 (0.34) | RAB9ATSHRL3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3288933-B1 | OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | MUSC FOUND FOR RES DEV (US) | 2021-10-06 | — | — | EP | claimed |
| US-20180134659-A1 | OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT | 2018-05-17 | — | — | US | claimed |
| EP-3288933-B1 | OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | MUSC FOUND FOR RES DEV (US) | 2021-10-06 | — | — | EP | disclosed |
| US-10370328-B2 | Oxindole compounds and pharmaceutical compositions thereof | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180134659-A1 | OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370328-B2 | Oxindole compounds and pharmaceutical compositions thereof | PARK7, OPRK1, COMT | RAB9A 922/4885TSHR 2005/4885L3MBTL1 3240/4885 |
| US-20180134659-A1 | OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | PARK7, OPRK1, COMT | RAB9A 922/4885TSHR 2005/4885L3MBTL1 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.